• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Centivax Raises $45M to Commercialize First Universal Flu Vaccine

by Syed Hamza Sohail 07/08/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

–  Centivax, a biotech company developing durable, universal vaccines, today announced the close of a $45 million Series A led by Steve Jurvetson’s Future Ventures, with participation from NFX, BOLD Capital, Base4, Kendall Capital Partners, Amplify Bio, and existing investors.

– The new funding will advance Centivax’s lead universal flu vaccine candidate through CMC development and into a Phase I trial within eight months.

Centivax Accelerates Universal Vaccine Development with Broad-Spectrum Pipeline and Strategic Backing

Centivax is pioneering a new frontier in immunology through a proprietary computational immune-engineering platform designed to create universal vaccines and therapies that provide durable protection across entire categories of fast-evolving threats. Based in South San Francisco, the company is advancing a versatile pipeline that spans infectious diseases, oncology, and chronic health conditions—positioning itself at the intersection of bioengineering innovation and unmet global health needs.

At the forefront of this effort is Centivax’s lead clinical candidate for influenza, targeting a global flu market valued at over $7 billion. The candidate will undergo clinical testing using the gold-standard hemagglutination-inhibition (HAI) assay, directly comparing its ability to protect against over 20 influenza strains—including seasonal, mismatched, and pandemic variants—with that of conventional flu vaccines. Preclinical studies, including work in human organoids and animal models, have demonstrated cross-strain protection, notably against high-concern threats such as H5N1 avian influenza.

What distinguishes Centivax is the broad adaptability of its epitope-focusing technology. Originally designed to overcome antigenic drift and escape in viral pathogens, the platform has proven extensible across a range of targets, including RSV/hMPV, herpesviruses, HIV, and malaria. It is now being leveraged to explore solutions in oncology, autoimmunity, neurodegeneration, cardiovascular disease, and even universal antivenoms—underscoring its potential to reshape how medicine responds to both infectious and non-infectious disease burdens.

“This financing positions us to help the U.S. government meet its goal of a universal flu vaccine within five years,” said CEO Dr. Jacob Glanville. “Our platform’s versatility enables us to tackle a spectrum of rapidly mutating targets, from viruses to venom toxins.”

The leadership team combines deep scientific expertise with proven execution in biotechnology. Dr. Glanville, who previously founded Distributed Bio and led over 75 discovery programs in collaboration with major pharmaceutical partners such as Pfizer, Gilead, and Teva, continues to steer Centivax’s scientific vision. Supporting him are key figures such as Dr. Jerald Sadoff, Chief Medical Officer, who has played a pivotal role in the clinical development and approval of 14 vaccines—including Gardasil, Rotateq, and J&J’s COVID-19 vaccine Jcovden—across tenures at Merck, Johnson & Johnson, and Crucell.

Chief Scientific Officer and co-founder Dr. Sawsan Youssef, whose immunotherapy work at Pfizer contributed to the development of sasanlimab, brings extensive experience in translational science. Stephanie Wisner, co-founder and Chief Business Officer, brings a strategic lens from her time at ARCH Venture Partners and is the author of Building Backwards to Biotech. They are joined by Chief Innovation Officer Gus Zeiner, Chief Operations Officer David Tsao, and Chief Technology Officer Nicholas Bayless.

Centivax’s growth has been propelled not only by venture capital but also by over $24 million in competitive, non-dilutive funding. The company’s initial $2 million award came through the Bill & Melinda Gates Foundation’s “Grand Challenge: End the Pandemic Threat,” followed by significant support from CEPI, the NIH, the Military Infectious Diseases Research Program, and the U.S. Naval Medical Research Command, among others.

With a differentiated platform, cross-functional expertise, and validation from global scientific and funding institutions, Centivax is positioning itself as a leading force in the pursuit of universal protection against humanity’s most complex immunological threats.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance

Most-Read

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

CB Insights’ 2026 Digital Health 50 Reveals How Agentic AI Is Becoming the Clinical Provider and Medication Access Engine

Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

M&A: Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

CVS Rebrands Health Services Segment, Launches Model for Retail Pharmacy Reimbursement

CVS Health Formalizes Tax-Free Split-Off to Carve Out CVS Pharmacy by 2028

SAMHSA and ONC Invest $20M in Behavioral Health IT Initiative

ONC Finalizes HTI-5 Deregulatory Rule to Cut $1.55B in Health IT Compliance and Accelerate FHIR APIs

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |